Skip to main content
PhoenixBio Co.,Ltd. logo

PhoenixBio Co.,Ltd. — Investor Relations & Filings

Ticker · 6190 ISIN · JP3803010002 T Professional, scientific and technical activities
Open in API
Filings indexed 63 across all filing types
Latest filing 2022-11-14 Report Publication Anno…
Country JP Japan
Listing T 6190

About PhoenixBio Co.,Ltd.

https://phoenixbio.co.jp/

PhoenixBio is a contract research organization (CRO) specializing in translational animal models for the pharmaceutical industry. The company's core product is the PXB-mouse®, a proprietary chimeric mouse model featuring a liver that is highly repopulated (over 70%) with functional human hepatocytes. This humanized liver model is utilized globally in preclinical studies to evaluate drug metabolism, pharmacokinetics, and toxicity. In addition to supplying the PXB-mouse® and primary human hepatocytes (PXB-cells®), PhoenixBio provides comprehensive, quality-controlled contract study services to support drug discovery and early development projects.

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-4-8 of the Financial Instruments and Exchange Act of Japan, which accompanies a Quarterly Report (Dai-ni shihanki hokokusho). Since this is a formal regulatory filing confirming the accuracy of the quarterly financial report, and it is a specific regulatory requirement in Japan for the submission of quarterly reports, it falls under the category of Regulatory Filings (RNS) as it is a supporting regulatory document rather than the quarterly report itself or a simple announcement.
2022-11-14 Japanese
四半期報告書－第22期第2四半期(令和4年7月1日－令和4年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for PhoenixBio Co., Ltd. covering the second quarter of the fiscal year 2022 (April 1, 2022, to September 30, 2022). It contains detailed financial statements, including the balance sheet, income statement, and cash flow statement, as well as management's analysis of financial results. This fits the definition of an Interim/Quarterly Report (IR). Q2 2023
2022-11-14 Japanese
確認書
Regulatory Filings
2022-08-12 Japanese
四半期報告書－第22期第1四半期(令和4年4月1日－令和4年6月30日)
Interim / Quarterly Report
2022-08-12 Japanese
内部統制報告書－第21期(令和3年4月1日－令和4年3月31日)
Governance Information Classification · 100% confidence The document is an 'Internal Control Report' (内部統制報告書) filed under the Financial Instruments and Exchange Act of Japan. It details the company's framework, scope, and evaluation results regarding internal controls over financial reporting. As this is a specific regulatory filing required by Japanese law and does not fit into categories like 10-K (Annual Report) or ER (Earnings Release), it is best classified as a Regulatory Filing.
2022-06-29 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan, specifically accompanying an Annual Securities Report (Yuuka Shouken Houkokusho). Since the document is a short, formal regulatory filing confirming the accuracy of the annual report rather than the annual report itself, and it does not fit into specific categories like '10-K' or 'AR', it is classified as a general regulatory filing. FY 2022
2022-06-29 Japanese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.